Sitagliptin

Routes
Oral (PO)
Half-Life (t½)
PO: 10.4h
Formula
C16H15F6N5O
Molecular Weight
407.31 g/mol
PubChem CID
4369359
Aliases
Januvia, MK-0431

Pharmacological Mechanism

Competitive, reversible DPP-4 (dipeptidyl peptidase-4) inhibitor — blocks degradation of the endogenous incretins GLP-1 and GIP, raising their plasma levels 2–3× and potentiating glucose-dependent insulin release plus glucagon suppression. Weight-neutral, low hypoglycaemia risk (glucose-dependent action). CV-neutral (TECOS trial).

Half-Life & Elimination Curve (PO: 10.4h)

100%50%25%12.5%0%0h0×t½10.4h1×t½20.8h2×t½31.2h3×t½41.6h4×t½52h5×t½0×t½ (0h): 100% remaining (~0.444 mg/L)1×t½ (10.4h): 50% remaining (~0.222 mg/L)2×t½ (20.8h): 25% remaining (~0.111 mg/L)3×t½ (31.2h): 12.5% remaining (~55.5 µg/L)4×t½ (41.6h): 6.3% remaining (~27.7 µg/L)5×t½ (52h): 3.1% remaining (~13.9 µg/L)
Elimination (PO)Effect Site (ke0)
  • 0×t½0h100% (0.444 mg/L)
  • 1×t½10.4h50% (0.222 mg/L)
  • 2×t½20.8h25% (0.111 mg/L)
  • 3×t½31.2h12.5% (55.5 µg/L)
  • 4×t½41.6h6.3% (27.7 µg/L)
  • 5×t½52h3.1% (13.9 µg/L)
Elimination t½10.4h (PO)
Rate Constant (ke)0.0666 h⁻¹
Est. Peak (Cmax)0.444 mg/L
Clearance (CL)13.1 L/h
97% Washout (5×t½)52h

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

Interactions

Chemical Structure & Identifiers

References